14 Questions to Ask Your Doctor About Transthyretin Amyloid Cardiomyopathy

If you’ve been diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), you probably have a lot of questions.
For example, you may want to know the causes of the heart condition and what symptoms and potential complications to expect. You’re also likely interested in available treatment options and overall prognosis.
That’s why it’s best to consult a cardiologist with expertise in the condition once you’ve received your ATTR-CM diagnosis, says Frederick L. Ruberg, MD, chief of cardiovascular medicine at Boston Medical Center and section chief of cardiovascular medicine at Boston University Chobanian and Avedisian School of Medicine.
In ATTR-CM, the protein can become misshapen, and clumps of malformed proteins, called amyloids, can form and build up in the heart, nerves, and other organs.
“Not all physicians have a full understanding of what transthyretin amyloid cardiomyopathy is,” says Dr. Ruberg. But learning more about ATTR-CM can help you better communicate with your doctors and manage your symptoms, he adds. Here are some questions to ask your doctor:
1. What Type of Transthyretin Amyloid Cardiomyopathy Do I Have?
There are two types of ATTR-CM: hereditary and wild.
2. What Are My Treatment Options?
Previously, the only treatment for ATTR-CM was an organ transplant of the heart, the liver, or both. Now, both hereditary and wild-type ATTR-CM are most commonly treated with medications designed to slow or stop the buildup of amyloid deposits.
Medications called ATTR silencers are designed to control transthyretin production or prevent abnormal transthyretins from accumulating in your heart.
3. What Can I Expect From Treatment?
None of these options promises a cure. But they may prevent progression of the disease and, in some cases, improve your symptoms, says Noel R. Dasgupta, MD, an associate professor of clinical medicine at Indiana University School of Medicine in Indianapolis, and member of the Indiana University Amyloidosis Center.
4. Will I Need a Heart or Liver Transplant?
If ATTR-CM has progressed to advanced heart failure, heart transplantation may be considered. This is usually only an option for people with hereditary ATTR-CM, who tend to be younger, because the wild type tends to strike when a person is older and a heart transplant isn’t feasible, Ruberg says.
In the past, according to Dr. Dasgupta, some people have undergone heart and liver transplants simultaneously to address ATTR-CM, although this is increasingly rare. Liver transplantation is done in hereditary amyloidosis to stop the production of abnormal transthyretin.
5. What Steps Can I Take to Manage My Symptoms?
The best way to manage symptoms is to stick to your doctor-prescribed treatment, Ruberg says.
“For patients with ATTR-CM who have congestive heart failure, the main treatment focuses on control of heart failure, which typically requires medications designed to manage fluid overload in the heart and control heart arrhythmias,” says Dasgupta.
6. Why Am I Short of Breath, and Is There Anything I Can Do About It?
7. When Should I Seek Emergency Medical Help?
“Passing out, or syncope, could be a sign of a serious heart arrhythmia,” says Dasgupta. “If you have severe shortness of breath, chest pain, or palpitations, these could be signs of a serious medical problem that requires emergency care.”
8. Can Diet or Lifestyle Changes Improve ATTR-CM?
Although diet and lifestyle changes won’t cure your ATTR-CM, Ruberg emphasizes, they can help you manage the symptoms and reduce your risk of advanced congestive heart failure.
As for staying physically active, you should try to get some exercise, under the guidance of your healthcare professionals. Although it’s likely that your ATTR-CM symptoms may affect your ability to exercise, it’s important to try to stay physically fit. Even walking can help, Ruberg says.
9. Who Should Be on My ATTR-CM Care Team?
“I think it’s helpful to visit with a cardiologist at a center that specializes in ATTR-CM,” Ruberg says. “They will have the best understanding of the condition and can get you into a clinical trial for the newest treatments, if you’re eligible.”
10. What Tests Will I Need and How Often?
Your cardiologist should order a baseline electrocardiogram (ECG) and echocardiogram to monitor your heart function. They may then perform periodic ECGs or cardiac magnetic resonance imaging (MRI), if needed, to monitor your heart’s electrical system, function, and structure.
A nuclear medicine scan may also be needed to see if your treatment is controlling or reducing the amyloid buildup in your heart.
11. What Are the Potential Complications of ATTR-CM? Are There Any Symptoms That Signal an Emergency?
According to Ruberg, complications associated with transthyretin amyloid cardiomyopathy include, most notably, progression to congestive heart failure and the development of related conditions, such as heart rhythm problems, peripheral neuropathy, and constipation or diarrhea.
People with ATTR-CM are not at increased risk for a heart attack, he notes, but are at risk for serious heart rhythm problems that would require immediate attention.
Many of the symptoms of congestive heart failure mirror those of ATTR-CM, so if you experience any of them while on treatment, call your doctor.
12. Should I Be Monitored for Atrial Fibrillation?
Atrial fibrillation, or afib, is a common complication of ATTR-CM, according to Ruberg. If you have a history of afib, talk to your doctor about the best ways to monitor your heart function. Most patients with afib and ATTR-CM will need blood-thinning medication to reduce the risk of stroke.
13. Should I Be Undergoing Treatment for Congestive Heart Failure?
Unfortunately, many of the drugs used to treat congestive heart failure, such as ACE inhibitors and beta-blockers, aren’t well tolerated by people with ATTR-CM and cause side effects and complications, Ruberg explains.
If you are being treated for congestive heart failure and have been diagnosed with ATTR-CM, talk to your doctor about the medications you take and see if you need to make any changes.
14. Does Having ATTR-CM Mean I May Get Amyloid Light-Chain Amyloidosis?
Amyloid light-chain (AL) amyloidosis is a bone marrow disorder that, like ATTR-CM, is caused by misshapen proteins. Although the two conditions are similar, the proteins are very different, and having one doesn’t put you at higher risk of getting the other, Ruberg notes.
But, he adds, if you have AL amyloidosis and it moves to your heart, it can carry a far worse prognosis than standard ATTR-CM.
“I definitely urge my patients to educate themselves about all forms of amyloidosis,” he says. “While I also caution them that there’s a lot we still don’t know about these conditions, they should stay as up to date and on top of their health as possible.”

Chung Yoon, MD
Medical Reviewer

Brian P. Dunleavy
Author
Brian P. Dunleavy is a writer and editor with more than 25 years of experience covering issues related to health and medicine for both consumer and professional audiences. As a journalist, his work has focused on new research in the treatment of infectious diseases, neurological disorders (including multiple sclerosis and Alzheimer's disease), and pain management. His work has appeared in ADDitude, Consumer Reports, Health, Pain Medicine News, and Clinical Oncology News.
Dunleavy is the former editor of the infectious disease special edition at ContagionLive.com. He is also an experienced sports reporter who has covered the NFL, MLB, NBA, NHL, and professional soccer for a number of publications. He is based in New York City.
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM). American Heart Association. May 29, 2024.
- Brito D et al. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart. October 26, 2023.
- TTR Gene: Transthyretin. MedlinePlus. November 8, 2023.
- Wild-Type (Senile) ATTR Amyloidosis. Stanford Medicine.
- Morfino P et al. Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopath. Pharmaceutics. April 3, 2023.
- Lifestyle Changes to Prevent a Heart Attack. American Heart Association. October 16, 2023.
- Transthyretin Amyloidosis (ATTR-CM). Cleveland Clinic. May 1, 2022.
- Garcia-Pavia P et al. Expert Consensus on the Monitoring of Transthyretin Amyloid Cardiomyopathy. European Journal of Heart Failure. June 2021.